Michael A. Metzger, Chief Executive Officer at Syndax Pharmaceuticals Inc (SNDX), sold 32,375 shares at $24.24 ($785K) on 2026-07-08, disclosed to the SEC on 2026-07-09.
Scheduled sale ($785k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| SNDX | SELL | 2026-02-06 | $153K | — | Filing → |
| SNDX | SELL | 2025-09-08 | $5.2M | — | Filing → |
| SNDX | SELL | 2025-07-18 | $140K | — | Filing → |